Clinical Trial Update: Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry [Phase 2]

View source ↗

Summary

Phase 2 trial update on optimizing therapy for metastatic differentiated thyroid cancer using 124I PET dosimetry.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• 124I

Snippet

Sponsor: Carlo Chiesa | Conditions: Metastatic Differentiated Thyroid Cancer | Phase 2 | Status: UNKNOWN